Study of Liver Enzymes Levels in Patients on Antiepileptic Therapy

Authors

  •   Shyamala M. Rubini Department of Biochemistry, Thanjavur Medical College, Thanjavur - 613004, Tamil Nadu
  •   M. Ramadevi Department of Biochemistry, Thanjavur Medical College, Thanjavur - 613004, Tamil Nadu

DOI:

https://doi.org/10.65129/health.v1i3.94

Keywords:

Antiepileptic drugs, Epilepsy, Hepatotoxicity, Liver enzymes

Abstract

Background: Antiepileptic drugs induce and increase production of hepatic enzymes. The adverse metabolic effects of antiepileptic therapy have become main concern. The routine screening of hepatic enzymes during the chronic use of antiepileptic drug is recommended. Aim: To determine the correlation between liver enzymes and antiepileptic drugs. Methods: The study includes 50 neurosurgery patients who took antiepileptics for more than 6 months, including patients with single drug regime and multi drug regime for seizure control. Single drug regime includes patients on phenytoin, multidrug regime includes patients on treatment with phenytoin, sodium valproate, levetiracetam and carbamazepine. Liver enzymes estimated by IFCC method. LFT samples run by fully auto analyser. Results: In this study, the AST and ALT levels were not found to be raised in study patient’s group. ALP levels were raised in patients on multidrug regime. However, the levels were not significantly raised. Conclusion: Patients on Antiepileptic therapy should be regularly checked for LFT especially on patients with multi drug therapy. As early detection and treatment can prevent the further complications and will be helpful during the management of patients on Antiepileptic therapy.

Downloads

Download data is not yet available.

Downloads

Published

2025-09-24

How to Cite

Rubini, S. M., & Ramadevi, M. (2025). Study of Liver Enzymes Levels in Patients on Antiepileptic Therapy. Journal of Health and Technology, 1(3), 170–174. https://doi.org/10.65129/health.v1i3.94

Issue

Volume 1, Issue 3, September 2025

Section

Research Article

License

Copyright (c) 2026 Journal of Health and Technology

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Crossref
Scopus
Google Scholar
Europe PMC

References

1. Nikalje A, Ghodke M, Girbane A. GABA modulating agents: a brief review. Asian journal of Biological Sciences. 2011; 4:201e20. https://doi.org/10.3923/ajbs.2011.201.220

2. Ahmad M. Epilepsy: stigma and management. Current Research in Neuroscience. 2011; 201:1e14. https://doi.org/10.3923/crn.2011.1.14

3. Arroyo S, de la Morena A. Life-threatening adverse events of antiepileptic drugs. Epilepsy Research. 2001; 47(1):155e74 https://doi.org/10.1016/S0920-1211(01)00306-0 PMid:11673030.

4. Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure. 2006; 15(3):156e64. https://doi.org/10.1016/j.seizure.2005.12.009 PMid:16442314.

5. Lee WM. Drug-induced hepatotoxicity. New England Journal of Medicine. 2003; 349(5):474e85. https://doi.org/10.1056/NEJMra021844 PMid:12890847.

6. Bjornsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurologic Scandinavica. 2008; 118(5):281e90. https://doi.org/10.1111/j.1600-0404.2008.01009 PMid: 18341684.

7. Christiansen T. Serum vitamin D metabolites in epileptic patients treated with two different anticonvulsants. Acta Neurologic Scandinavica. 1982; 66:335e41. https://doi.org/10.1111/j.1600-0404.1982.tb06853 PMid:6982586.

8. O’Hare JA, Duggan B, O’Driscoll D, Callaghan N. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurologic Scandinavica. 1980; 62(5):282e6. https://doi.org/10.1111/j.1600-0404.1980.tb03037 PMid: 7468150.

9. Deda G, Kunak B, Yilmaz S, Gurer V, Tezic¸ T, Karagol U. Antikonvulsan ilacalan cocuklarda serum alkalen fosfataz duzeyleri, 25-OH vitamin D duzeyleri ve rikets. Anatolian Journal of Pediatrics. 1993; 2:10e3.

10. Sonmez FM, Demir E, Orem A, Yildirmis S, Orhan F, Aslan A, et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. Journal of child neurology. 2006; 21(1):70e4. https://doi.org/10.1177/08830738060210011301 PMid:16551457.

11. Spiller HA, Spiller H, Krenzelok EP, Klein-Schwartz W, Winter ML, Weber JA, et al. Multicenter case series of valproic acid ingestion: serum concentrations and toxicity. Clinical Toxicology. 2000; 38(7):755e60. https://doi.org/10.1081/CLT-100102388 PMid:11192462.

12. Sussman NM. Hepatotoxicity of valproic acid. Neurology. 1979; 29:601. https://doi.org/10.1212/WNL.29.10.1430 PMid:384297.

13. Craig S. Phenytoin poisoning. Neurocritical Care. 2005; 3(2):161e70. https://doi.org/10.1385/NCC:3:2:161 PMid: 16174888.

14. Perucca E, Hedges A, Makki KA, Ruprah M, Wilson JF, Richens A. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. British Journal of Clinical pharmacology. 2004; 58(7): S854e63. https://doi.org/10.1111/j.1365-2125.2004.02311 PMid:15595983 PMCid: PMC1884674.

15. Spielberg SP, Gordon GB, Blake DA, Goldstein DA, Herlong HF. Predisposition to phenytoin hepatotoxicity assessed in vitro. New England Journal of Medicine. 1981; 305(13):722e7.

https://doi.org/10.1056/NEJM198109243051302 PMid: 6790991.

16. Hussein RRS, Soliman RH, Abdulhaleem Ali AM, Tawfeik MH, Abdelrahim MEA. Effect of antiepileptic drugs on liver enzymes. Beni-Suef Univ J Basic Appl Sci. 2013; 2:14. e1-14. e6. https://doi.org/10.1016/j.bjbas.2013.09.002.